Navigation Links
Cempra Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
Date:3/2/2011

CHAPEL HILL, N.C., March 2, 2011 /PRNewswire/ -- Cempra Pharmaceuticals Inc. today announced that Prabhavathi Fernandes, president and chief executive officer, will present at the Cowen and Company 31st Annual Health Care Conference at 1:30 p.m. EST, March 7, 2011, at The Boston Marriott Copley Place in Boston.  Dr. Fernandes will provide an overview of the company's two leading antibiotic clinical programs, solithromycin for community-acquired bacterial pneumonia and TAKSTATM for the oral treatment of gram positive pathogens including methicillin-resistant S. aureus (MRSA).

About Cempra PharmaceuticalsFounded in 2006, Cempra Pharmaceuticals is a privately-held, clinical-stage biotechnology company focused on developing antibacterials to address critical medical needs. Two lead products, both in late-stage clinical trials, address the urgent and increasing need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. Cempra is well-funded and is committed to developing commercially viable products through consideration of pricing and reimbursement issues throughout its products' lifecycles. The company is also utilizing its proprietary chemistry technology to develop macrolides without antibacterial activity for non-antibiotic uses in motilin receptor activity, anti-inflammatory activity and GnRH receptor antagonism. Additional information about Cempra can be found at www.cempra.com. Media Contacts:Robert E. Flamm, Ph.D.Russo Partners, LLC(212) 845-4226 Robert.flamm@russopartnersllc.comTony Russo, Ph.D.Russo Partners, LLC(212) 845-4251Tony.russo@russopartnersllc.com
'/>"/>

SOURCE Cempra Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related biology technology :

1. Cempra Pharmaceuticals Profiles the Broad Spectrum and Potent Activity Profile of Solithromycin (CEM-101) at the 5th Annual PHEMCE Stakeholders Workshop and BARDA Industry Day
2. Cempra Pharmaceuticals Announces Appointment of John H. Johnson to Board of Directors
3. Inovio Pharmaceuticals Foot-and-Mouth Disease DNA Vaccine Introduces Critical Advantages in Fight Against Most Serious Farm Animal Disease
4. MAP Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results
5. Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2010 Financial Results
6. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2010 Financial Results on March 4, 2011
7. Anthera Pharmaceuticals to Present at the Citi 2011 Global Health Care Conference
8. Anthera Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results and Operational Update
9. Savient Pharmaceuticals to Present at the Citi 2011 Global Healthcare Conference
10. Optimer Pharmaceuticals, Inc. Announces Exercise in Full of Underwriters Option to Purchase Additional Shares and Closing of Public Offering of Common Stock
11. Savient Pharmaceuticals Announces Executive Appointments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013  Rahal Letterman Lanigan ... human cord blood stem cell banking and therapeutics, announced ... the No. 16 Acorn Stairlifts Indy car driven by ... the remainder of the IZOD IndyCar 2013 season.   ... will work to support awareness of umbilical cord blood ...
(Date:5/23/2013)... 23, 2013  Saddleback Memorial Medical Center in ... first hospital on the West Coast to perform a ... option provides women with a state-of-the-art, minimally invasive approach ... Winter , M.D., a highly regarded ... director of minimally invasive surgery at Saddleback Memorial, led ...
(Date:5/23/2013)... Ill. , May 23, 2013 Z ... providing value-added ingredients to a variety of industries, announced ... in a panel discussion at this year,s National Restaurant ... 20-21, 2013, on behalf of the Research Chefs Association.  ... for Restaurants: The Good, the Bad and the Ugly," ...
(Date:5/23/2013)... , May 23, 2013  Verenium Corporation (Nasdaq: ... focused on the development and commercialization of high-performance enzymes, ... Chief Financial Officer, will present at two upcoming conferences. ... Black will present at the Second Annual Marcum LLP ... Grand Hyatt Hotel in New York City.  The presentation ...
Breaking Biology Technology:StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 2StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 3Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 2Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 3Z Trim's Chef Erin Ryan sits on Expert Panel at NRA Show 2Z Trim's Chef Erin Ryan sits on Expert Panel at NRA Show 3Verenium To Present At Two Upcoming Conferences 2Verenium To Present At Two Upcoming Conferences 3
... BioPharma, Inc. (OTC Bulletin Board: DORB) (DOR or the ... results for the first quarter of 2009. DOR,s revenues ... million compared to $0.7 million for the first quarter ... to decreased research and development amounts drawn down from ...
... - Investigating the Real Burden ... Pressure Goal and SHARE(ing) the Knowledge,( http://www.SHARE-hypertension.com ) ... committee announce the launch of Supporting,Hypertension Awareness & ... (17th May). SHARE is a collaborative program of ...
... the Georgia Institute of Technology and the National ... measured the unusual energy spectrum of graphene, a ... tantalized and puzzled scientists since its discovery in ... Science ,* their work adds new detail ...
Cached Biology Technology:DOR BioPharma Reports 1st Quarter 2009 Financial Results and Reviews Recent Accomplishments 2DOR BioPharma Reports 1st Quarter 2009 Financial Results and Reviews Recent Accomplishments 3DOR BioPharma Reports 1st Quarter 2009 Financial Results and Reviews Recent Accomplishments 4DOR BioPharma Reports 1st Quarter 2009 Financial Results and Reviews Recent Accomplishments 5SHARE Program Launched to Address the Challenges of Achieving Blood Pressure Goal 2SHARE Program Launched to Address the Challenges of Achieving Blood Pressure Goal 3SHARE Program Launched to Address the Challenges of Achieving Blood Pressure Goal 4SHARE Program Launched to Address the Challenges of Achieving Blood Pressure Goal 5Graphene yields secrets to its extraordinary properties 2
(Date:5/22/2013)... Legionella pneumophila bacteria is responsible for legionellosis, an ... to infect us, this pathogen has developed a complex ... in our cells, thus avoiding these acting against the ... research centre, CIC bioGUNE, in which teams from the ... the National Supercomputation Centre in Barcelona (BSC) have also ...
(Date:5/21/2013)... long time that some creatures evolve more quickly than ... But it may be that height plays a role, ... U. S. National Evolutionary Synthesis Center. , In ... journal Nature Communications , Lanfear and colleagues report ... a database of global patterns in plant height for ...
(Date:5/21/2013)... USC have found that a class of pharmaceuticals can ... , The drugs, known as "TSPO ligands," are currently ... at the effects of TSPO ligand in young adult ... in aged mice when pathology was quite severe," said ... of Gerontology. "TSPO ligand reduced measures of pathology and ...
Breaking Biology News(10 mins):Mechanism discovered which aids Legionella to camouflage itself in the organism 2Small but speedy: Short plants live in the evolutionary fast lane 2Drugs found to both prevent and treat Alzheimer's disease in mice 2
... the structure and function of cells and the process ... ends constantly elongate and retreat in a thrashing frenzy ... Medusa's hair. Known prosaically as "dynamic instability," this ongoing ... workings of microtubules in the cell. , For the ...
... requires treatment of the sexual partners of infected patients. ... antibiotics to give their partners is more effective than ... to an article in the Sept. 1 issue of ... or gonorrhea were more likely to see and talk ...
... can burrow into a tumor, seal the exits and ... leaving healthy cells unscathed. , MIT researchers have designed ... double-acting, drug-packing "nanocell" proved effective and safe, with prolonged ... lung cancer--in mice. , The work will be reported ...
Cached Biology News:The making and breaking of microtubules 2The making and breaking of microtubules 3The making and breaking of microtubules 4The making and breaking of microtubules 5Measurement Challenges In Detecting Cancer Biomarkers 2Measurement Challenges In Detecting Cancer Biomarkers 3MIT engineers an anti-cancer smart bomb 2
... BioLogic Maximizer kit, 110 to 220 ... monitoring and doubles flow rates and ... systems. The kit includes the Maximizer ... starter kit, tubing kit, system cable ...
... antifade reagent is used to ... standard fluorescence microscopy. The unique ... a wide variety of fixed ... fluorescein, rhodamine, sulforhodamine 101, coumarin, ...
... Signets FAST RED Chromogen System consists ... FAST RED reacts in the presence of ... minimal background noise. The FAST RED ... ,The System Contains: , , Vial ...
... Dodeca silver stain kits are optimized ... including Bio-Rad Dodeca stainers. This silver ... of proteins in polyacrylamide gels and ... includes sensitizer concentrate, silver reagent concentrate, ...
Biology Products: